Current evidence for the induction of autoimmune rheumatic manifestations by cytokine therapy (Q33973488)

30 July 2017

1 reference

title

Current evidence for the induction of autoimmune rheumatic manifestations by cytokine therapy (English)

1 reference

30 July 2017

2

Isenberg DA

1 reference

30 July 2017

Ioannou Y

1

1 reference

30 July 2017

1 July 2000

1 reference

30 July 2017

Arthritis & Rheumatology

1 reference

30 July 2017

43

1 reference

30 July 2017

1431-1442

1 reference

30 July 2017

7

1 reference

Alpha interferon for induction of remission in hairy-cell leukemia

30 July 2017

1 reference

https://api.crossref.org/works/10.1002%2F1529-0131%28200007%2943%3A7%3C1431%3A%3AAID-ANR3%3E3.0.CO%3B2-E

Interferon alfa-2B in chronic lymphatic leukemia of the B-cell type

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1529-0131%28200007%2943%3A7%3C1431%3A%3AAID-ANR3%3E3.0.CO%3B2-E

Treatment of malignant endocrine pancreatic tumours with human leucocyte interferon.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1529-0131%28200007%2943%3A7%3C1431%3A%3AAID-ANR3%3E3.0.CO%3B2-E

Granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor (1).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1529-0131%28200007%2943%3A7%3C1431%3A%3AAID-ANR3%3E3.0.CO%3B2-E

A Controlled Trial of Interferon Gamma to Prevent Infection in Chronic Granulomatous Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1529-0131%28200007%2943%3A7%3C1431%3A%3AAID-ANR3%3E3.0.CO%3B2-E

Side effects of high-dose interferon therapy for chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1529-0131%28200007%2943%3A7%3C1431%3A%3AAID-ANR3%3E3.0.CO%3B2-E

A survey of adverse events in 11,241 patients with chronic viral hepatitis treated with alfa interferon.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1529-0131%28200007%2943%3A7%3C1431%3A%3AAID-ANR3%3E3.0.CO%3B2-E

Systemic lupus erythematosus in a child receiving long-term interferon therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1529-0131%28200007%2943%3A7%3C1431%3A%3AAID-ANR3%3E3.0.CO%3B2-E

Exacerbation of symptoms of autoimmune disease in patients receiving alpha-interferon therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1529-0131%28200007%2943%3A7%3C1431%3A%3AAID-ANR3%3E3.0.CO%3B2-E

The 1982 revised criteria for the classification of systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1529-0131%28200007%2943%3A7%3C1431%3A%3AAID-ANR3%3E3.0.CO%3B2-E

Immunological disorders in C virus chronic hepatitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1529-0131%28200007%2943%3A7%3C1431%3A%3AAID-ANR3%3E3.0.CO%3B2-E

Mono-arthritis in a chronic hepatitis B patient after alpha-interferon treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1529-0131%28200007%2943%3A7%3C1431%3A%3AAID-ANR3%3E3.0.CO%3B2-E

Apoptosis in peripheral lymphocytes in systemic lupus erythematosus: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1529-0131%28200007%2943%3A7%3C1431%3A%3AAID-ANR3%3E3.0.CO%3B2-E

Enforced BCL2 expression in B-lymphoid cells prolongs antibody responses and elicits autoimmune disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1529-0131%28200007%2943%3A7%3C1431%3A%3AAID-ANR3%3E3.0.CO%3B2-E

Elevated soluble fas production in SLE correlates with HLA status not with disease activity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1529-0131%28200007%2943%3A7%3C1431%3A%3AAID-ANR3%3E3.0.CO%3B2-E

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1529-0131%28200007%2943%3A7%3C1431%3A%3AAID-ANR3%3E3.0.CO%3B2-E

Persistence of a reduced-collagen-producing phenotype in cultured scleroderma fibroblasts after short-term exposure to interferons

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1529-0131%28200007%2943%3A7%3C1431%3A%3AAID-ANR3%3E3.0.CO%3B2-E

Cytokine-induced autoimmune disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1529-0131%28200007%2943%3A7%3C1431%3A%3AAID-ANR3%3E3.0.CO%3B2-E

A randomized, double-blind study comparing twenty-four-week treatment with recombinant interferon-gamma versus placebo in the treatment of rheumatoid arthritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1529-0131%28200007%2943%3A7%3C1431%3A%3AAID-ANR3%3E3.0.CO%3B2-E

The Th1-Th2 model--what relevance to inflammatory arthritis?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1529-0131%28200007%2943%3A7%3C1431%3A%3AAID-ANR3%3E3.0.CO%3B2-E

Rheumatic disease following immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1529-0131%28200007%2943%3A7%3C1431%3A%3AAID-ANR3%3E3.0.CO%3B2-E

Inclusion body myositis and renal cell carcinoma. Report of two cases and review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1529-0131%28200007%2943%3A7%3C1431%3A%3AAID-ANR3%3E3.0.CO%3B2-E

Soluble interleukin-2 receptor, interleukin-2 and interleukin-4 in sera and supernatants from patients with progressive systemic sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1529-0131%28200007%2943%3A7%3C1431%3A%3AAID-ANR3%3E3.0.CO%3B2-E

Interleukin-2 in scleroderma: correlation of serum level with extent of skin involvement and disease duration

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1529-0131%28200007%2943%3A7%3C1431%3A%3AAID-ANR3%3E3.0.CO%3B2-E

Interferon beta decreases T cell activation and interferon gamma production in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1529-0131%28200007%2943%3A7%3C1431%3A%3AAID-ANR3%3E3.0.CO%3B2-E

Interferon-beta1A-induced polyarthritis in a patient with the HLA-DRB1*0404 allele

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1529-0131%28200007%2943%3A7%3C1431%3A%3AAID-ANR3%3E3.0.CO%3B2-E

Hepatitis C virus infection and autoimmunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1529-0131%28200007%2943%3A7%3C1431%3A%3AAID-ANR3%3E3.0.CO%3B2-E

Correlation between disease phenotype and genetic heterogeneity in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1529-0131%28200007%2943%3A7%3C1431%3A%3AAID-ANR3%3E3.0.CO%3B2-E

Amelioration of collagen-induced arthritis and suppression of interferon-gamma, interleukin-12, and tumor necrosis factor alpha production by interferon-beta gene therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1529-0131%28200007%2943%3A7%3C1431%3A%3AAID-ANR3%3E3.0.CO%3B2-E

Interferon-gamma and host antimicrobial defense: current and future clinical applications

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1529-0131%28200007%2943%3A7%3C1431%3A%3AAID-ANR3%3E3.0.CO%3B2-E

Cytokines and cytokine inhibitors or antagonists in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1529-0131%28200007%2943%3A7%3C1431%3A%3AAID-ANR3%3E3.0.CO%3B2-E

Recombinant human interferon gamma in the treatment of rheumatoid arthritis: double blind placebo controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1529-0131%28200007%2943%3A7%3C1431%3A%3AAID-ANR3%3E3.0.CO%3B2-E

Induction of antinuclear antibodies in patients with rheumatoid arthritis receiving treatment with human recombinant interferon gamma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1529-0131%28200007%2943%3A7%3C1431%3A%3AAID-ANR3%3E3.0.CO%3B2-E

Interferon-gamma in the treatment of systemic sclerosis: a randomized controlled multicentre trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1529-0131%28200007%2943%3A7%3C1431%3A%3AAID-ANR3%3E3.0.CO%3B2-E

In vivo treatment of (NZB X NZW)F1 lupus-like nephritis with monoclonal antibody to gamma interferon

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1529-0131%28200007%2943%3A7%3C1431%3A%3AAID-ANR3%3E3.0.CO%3B2-E

Antinuclear autoantibodies and lupus nephritis in transgenic mice expressing interferon gamma in the epidermis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1529-0131%28200007%2943%3A7%3C1431%3A%3AAID-ANR3%3E3.0.CO%3B2-E

Signal transducer and activator of transcription-1 and heat shock factor-1 interact and activate the transcription of the Hsp-70 and Hsp-90beta gene promoters

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1529-0131%28200007%2943%3A7%3C1431%3A%3AAID-ANR3%3E3.0.CO%3B2-E

Apoptosis of colorectal adenocarcinoma (COLO 201) by tumour necrosis factor-alpha (TNF-alpha) and/or interferon-gamma (IFN-gamma), resulting from down-modulation of Bcl-2 expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1529-0131%28200007%2943%3A7%3C1431%3A%3AAID-ANR3%3E3.0.CO%3B2-E

Immune thrombocytopenia and alpha-interferon therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1529-0131%28200007%2943%3A7%3C1431%3A%3AAID-ANR3%3E3.0.CO%3B2-E

Prolonged treatment with recombinant interferon gamma induces erythema nodosum leprosum in lepromatous leprosy patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1529-0131%28200007%2943%3A7%3C1431%3A%3AAID-ANR3%3E3.0.CO%3B2-E

Exacerbations of multiple sclerosis in patients treated with gamma interferon

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1529-0131%28200007%2943%3A7%3C1431%3A%3AAID-ANR3%3E3.0.CO%3B2-E

Effects of Interferon-γ Therapy on Thyroid Function, T-Lymphocyte Subpopulations and Induction of Autoantibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1529-0131%28200007%2943%3A7%3C1431%3A%3AAID-ANR3%3E3.0.CO%3B2-E

Effect of Alpha-Interferon Treatment in Patients with Hepatitis B e Antigen-Positive Chronic Hepatitis B

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1529-0131%28200007%2943%3A7%3C1431%3A%3AAID-ANR3%3E3.0.CO%3B2-E

10.1002/1529-0131(200007)43:7<1431::AID-ANR3>3.0.CO;2-E

21 January 2018

Identifiers

DOI

1 reference

30 July 2017

1 reference

PubMed ID

10902743